The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), according to The New York Times.
The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria, and tuberculosis in countries supported by USAID around the globe.
Uganda sought to dispel fears among HIV patients that a US aid freeze will interrupt treatment and promised that such programs will continue.
A stop in all of PEPFAR’s work shuttered clinics this week. Then, a new exemption for “life-saving” treatment left organizations uncertain.
Almost 136,000 babies are expected to be born with HIV in the next three months, mostly in Africa, because of the Trump administration’s “stop work order” on foreign assistance, according to a top research foundation.
The latest waiver appeared to give the go-ahead for funding for medication under PEPFAR, a major US programme against HIV/AIDS.
In patients with HIV, alcohol reduction after a 6-month intervention and adherence to isoniazid had no effect on the high levels of viral suppression reported at baseline.
Major barriers in screening for fatty liver disease in patients with HIV included uncertainties about testing, diagnostic data insufficiency, low priority, time constraints, and referral limitations.
The third day of the visit began with a launch of the Free to Shine Campaign, an initiative of the Organization of African First Ladies (OAFLAD) mobilising support to end new HIV infections and protect children and women.
But if it is not reversed permanently we can expect advances in life expectancy in sub-Saharan Africa of the past two decades to start coming undone. We can also expect HIV infection rates to start picking up again,
Canadian scientists say the uncertainty surrounding U.S. President Donald Trump's apparent pause on federal health spending could stall research on new drugs, vaccines, and treatments for cancer, dementia and more — including at labs in Canada.